FREQ News and Press, Frequency Therapeutics Inc. From 12/18/20

Event to be Held January 19, 2021 at 8:00 am ET; Will Feature Prominent Otolaryngology and Audiology Key Opinion Leaders Phase 2a Day-90 Readout for FX-322, Frequency’s Lead Product Candidate, for Acquired Sensorineural Hearing Loss Anticipated in Late Q1 2021; End ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chi...

Frequency Therapeutics (FREQ): Q3 GAAP EPS of -$0.16 beats by $0.16.Revenue of $11.25M (-53.6% Y/Y) beats by $5.37M.Cash, cash equivalents and short-term investments of $224.2M.Press Release For further details see: Frequency Therapeutics EPS beats by $0.16, beats on revenue

Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the body, so if successful, Frequency's technology should be broadly extendable into other areas...

Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter Frequency Therapeutics, ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Cynthia Feldmann to its Board of Di...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of ...

Company Overview Frequency Therapeutics ( FREQ ) is a clinical-stage company targeting sensorineural hearing loss ((SNHL)). SNHL, currently, affects more than 40M people in the US and that number is expected to grow by 20% over the next decade, representing a substantial domestic market. The...

Frequency Therapeutics ( FREQ +14.1% ) announces new data from a longer-term durability study of FX-322, demonstrating that some patients with chronic sensorineural hearing loss (SNHL) had significant improvement in key measures of hearing that were sustained for up to 21 months. ...

Evidence of Durable Hearing Improvements in Follow-Up with Patients from Phase 1/2 Study; Speech Intelligibility and Audibility Sustained for Up to 21 Months After Initial Dosing Data Highlighted at the 2020 American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS...